Chiappini Franck
INSERM U785, AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Université Paris-Sud. 14 avenue Paul Vaillant-Couturier, 94800 Villejuif, France.
Int J Hepatol. 2012;2012:684802. doi: 10.1155/2012/684802. Epub 2012 May 28.
Liver cancer is the fifth most common cancer in men and the seventh in women. During the past 20 years, the incidence of HCC has tripled while the 5-year survival rate has remained below 12%. The presence of circulating tumor cells (CTC) reflects the aggressiveness nature of a tumor. Many attempts have been made to develop assays that reliably detect and enumerate the CTC during the development of the HCC. In this case, the challenges are (1) there are few markers specific to the HCC (tumor cells versus nontumor cells) and (2) they can be used to quantify the number of CTC in the bloodstream. Another technical challenge consists of finding few CTC mixed with million leukocytes and billion erythrocytes. CTC detection and identification can be used to estimate prognosis and may serve as an early marker to assess antitumor activity of treatment. CTC can also be used to predict progression-free survival and overall survival. CTC are an interesting source of biological information in order to understand dissemination, drug resistance, and treatment-induced cell death. Our aim is to review and analyze the different new methods existing to detect, enumerate, and characterize the CTC in the peripheral circulation of patients with HCC.
肝癌是男性中第五大常见癌症，女性中第七大常见癌症。在过去20年中，肝细胞癌（HCC）的发病率增长了两倍，而5年生存率仍低于12%。循环肿瘤细胞（CTC）的存在反映了肿瘤的侵袭性。在HCC的发展过程中，人们进行了许多尝试来开发能够可靠检测和计数CTC的检测方法。在这种情况下，面临的挑战有：（1）针对HCC（肿瘤细胞与非肿瘤细胞）的特异性标志物很少；（2）这些标志物可用于量化血液中CTC的数量。另一个技术挑战是在数百万白细胞和数十亿红细胞中找到少量的CTC。CTC的检测和鉴定可用于估计预后，并可作为评估治疗抗肿瘤活性的早期标志物。CTC还可用于预测无进展生存期和总生存期。CTC是了解肿瘤扩散、耐药性和治疗诱导的细胞死亡的有趣生物学信息来源。我们的目的是回顾和分析现有的用于检测、计数和表征HCC患者外周循环中CTC的不同新方法。
